Cogent Biosciences (COGT) Total Non-Current Liabilities (2019 - 2026)

Cogent Biosciences (COGT) has 7 years of Total Non-Current Liabilities data on file, last reported at $295.3 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 355.65% year-over-year to $295.3 million in Q1 2026; TTM through Mar 2026 was $295.3 million, a 355.65% increase from a year earlier, with the FY2025 full-year figure at $301.2 million, up 320.6% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $295.3 million, down from $301.2 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for COGT reached as high as $301.2 million in Q4 2025 and fell as low as $43.4 million in Q4 2022.
• Historically, Total Non-Current Liabilities has averaged $145.0 million across 4 years, with a median of $117.4 million in 2025.
• Across the five-year window, Total Non-Current Liabilities surged 192.13% in 2022 and soared 355.65% in 2026, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $43.4 million in 2022, then surged by 65.1% to $71.6 million in 2024, then surged by 320.6% to $301.2 million in 2025, then retreated by 1.98% to $295.3 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $295.3 million in Q1 2026, $301.2 million in Q4 2025, and $121.1 million in Q3 2025.